Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 9/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.34 |
| ▸ | PDE8B | O95263 | 5/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20701858 | 1.00 | ADORA2A (0.41) | ADORA2AADORA2BTLR7TLR8ADORA3 | |
| SCHEMBL2195829 | 0.92 | TLR7 (0.44) | ADORA2AADORA2BTLR7TLR8ADORA3 | |
| SCHEMBL29697240 | 0.92 | TLR7 (0.44) | ADORA2AADORA2BTLR7TLR8ADORA3 | |
| SCHEMBL2197707 | 0.92 | TLR7 (0.44) | ADORA2AADORA2BTLR7TLR8ADORA3 | |
| SCHEMBL565796 | 0.92 | TLR7 (0.44) | ADORA2AADORA2BTLR7TLR8ADORA3 | |
| SCHEMBL3265229 | 0.90 | TLR7 (0.41) | ADORA2AADORA2BTLR7TLR8ADORA3 | |
| SCHEMBL567026 | 0.90 | TLR7 (0.41) | ADORA2AADORA2BTLR7TLR8ADORA3 | |
| SCHEMBL2199097 | 0.90 | TLR7 (0.37) | ADORA2AADORA2BTLR7TLR8ADORA3 | |
| SCHEMBL20275394 | 0.89 | ADORA2A (0.37) | ADORA2AADORA2BTLR7ADORA3ADORA1 | |
| SCHEMBL566720 | 0.89 | ADORA2A (0.37) | ADORA2AADORA2BTLR7ADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190038631-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | GLAXOSMITHKLINE LLC | 2019-02-07 | — | — | US | disclosed |
| US-20190038631-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | GLAXOSMITHKLINE LLC | 2019-02-07 | — | — | US | disclosed |
| US-10117873-B2 | 6-amino-purin-8-one compounds | GLAXOSMITHKLINE LLC (US) | 2018-11-06 | — | — | US | disclosed |
| EP-3336089-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | GlaxoSmithKline LLC (US) | 2018-06-20 | — | — | EP | disclosed |
| EP-3336089-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | GlaxoSmithKline LLC (US) | 2018-06-20 | — | — | EP | disclosed |
| US-20180117048-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | GLAXOSMITHKLINE LLC | 2018-05-03 | — | — | US | disclosed |
| US-20180117048-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | GLAXOSMITHKLINE LLC | 2018-05-03 | — | — | US | disclosed |
| US-20180117048-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | GLAXOSMITHKLINE LLC | 2018-05-03 | — | — | US | disclosed |
| US-9877968-B2 | 6-amino-purin-8-one compounds | GLAXOSMITHKLINE LLC (US) | 2018-01-30 | — | — | US | disclosed |
| US-9877968-B2 | 6-amino-purin-8-one compounds | GLAXOSMITHKLINE LLC (US) | 2018-01-30 | — | — | US | disclosed |
| US-8067426-B2 | 6-amino-purin-8-one compounds | GLAXOSMITHKLINE LLC (US) | 2011-11-29 | — | — | US | disclosed |
| US-20110229500-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | GLAXOSMITHKLINE LLC (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110229500-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | GLAXOSMITHKLINE LLC (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110229500-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | GLAXOSMITHKLINE LLC (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110135671-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | GLAXOSMITHKLINE LLC (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110135671-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | GLAXOSMITHKLINE LLC (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110135671-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | GLAXOSMITHKLINE LLC (US) | 2011-06-09 | — | — | US | disclosed |
| US-20100075995-A1 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075995-A1 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075995-A1 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110229500-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | IFNAR1, IFNG, STING1 | ADORA2A 14/4885ADORA2B 20/4885TLR7 10/4885 |
| US-20110135671-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | IFNG, IFNAR1, STING1 | ADORA2A 16/4885ADORA2B 24/4885TLR7 19/4885 |
| US-20190038631-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | IFNG, IFNAR1, IRF3 | ADORA2A 78/4885ADORA2B 46/4885TLR7 7/4885 |
| US-10117873-B2 | 6-amino-purin-8-one compounds | IFNG, IFNAR1, IRF3 | ADORA2A 78/4885ADORA2B 46/4885TLR7 7/4885 |
| US-20180117048-A1 | 6-AMINO-PURIN-8-ONE COMPOUNDS | IFNG, IFNAR1, IRF3 | ADORA2A 78/4885ADORA2B 46/4885TLR7 7/4885 |
| US-20100075995-A1 | COMPOUNDS | IFNG, IRF3, IFNAR1 | ADORA2A 1039/4885ADORA2B 631/4885TLR7 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.